Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
GT Biopharma
AddedFeb 19, 2024
UpdatedJun 18, 2026
GT Biopharma

GT Biopharma

Public

GT Biopharma, a global biotech firm, develops innovative drugs for cancer, myeloma, and other medical needs.

HQ
Brisbane, CA, US
Founded
1973
Overview
Compare
Fundraising
Employees
Website

GT Biopharma, Inc. (NASDAQ: GTBP) is a clinical-stage immuno-oncology company founded with the mission to develop innovative therapies for cancer and other unmet medical needs. Utilizing their proprietary NK cell engager (TriKE®) technology, GT Biopharma focuses on generating novel biopharmaceutical drugs targeting various cancers, including acute lymphocytic leukemia, non-Hodgkin's lymphoma, acute myeloid leukemia, and multiple solid tumors. The company's core vision is to revolutionize cancer treatment through advanced immunotherapy solutions.

Notable figures associated with GT Biopharma include key scientists and executives with extensive backgrounds in biotechnology and oncology. The company has attracted significant investment from both private and institutional investors, reflecting strong confidence in its potential. Key achievements include progressing several drug candidates into clinical trials and demonstrating promising preliminary results. GT Biopharma's impact lies in its potential to offer new hope to cancer patients worldwide through cutting-edge immunotherapy treatments.

GT Biopharma - Similar Companies

NextCure logo

NextCure

nextcure.com

GentiBio logo

GentiBio

gentibio.com

Genentech logo

Genentech

gene.com

BridgeBio Pharma logo

BridgeBio Pharma

bridgebio.com

Bolt Biotherapeutics logo

Bolt Biotherapeutics

boltbio.com

INmune Bio logo

INmune Bio

inmunebio.com

Equillium logo

Equillium

equilliumbio.com

Gritstone bio logo

Gritstone bio

gritstonebio.com

GO Therapeutics logo

GO Therapeutics

gotherapeutics.com

PharmaCyte Biotech logo

PharmaCyte Biotech

pharmacyte.com

NGM Biopharmaceuticals logo

NGM Biopharmaceuticals

ngmbio.com

Geron logo

Geron

geron.com

Legend Biotech logo

Legend Biotech

legendbiotech.com

Karyopharm Therapeutics logo

Karyopharm Therapeutics

karyopharm.com

Geneius logo

Geneius

geneius.com

GT Biopharma - Quick Facts

Who are GT Biopharma's competitors?

Companies similar to GT Biopharma include NextCure, GentiBio, Genentech and BridgeBio Pharma.

When was GT Biopharma founded?

GT Biopharma was founded in 1973.

Where is GT Biopharma's headquarters located?

GT Biopharma's headquarters is located in Brisbane, CA, US.

When was GT Biopharma's last funding round?

GT Biopharma's most recent funding round was for $6.5M (USD) in December 2022.

How much has GT Biopharma raised to-date?

As of Dec 30, 2022, GT Biopharma has raised a total of $71.1M (USD).

How many employees does GT Biopharma have?

GT Biopharma has 8 employees as of Feb 6, 2024.

GT Biopharma - Classification

Ownership
  • Public
Technology
  • Biotech
Geographic Exposure
  • Global
Revenue
  • Recurring
Customer
  • Enterprise
Main Product
  • Biopharmaceutical Drugs
Tags
  • Biotech
  • Healthcare
  • Healthtech
Unique IDs
  • ein: 941620407
  • secCik: 0000109657
  • ticker: GTBP
NAICS
  • 540000Professional, Scientific, and Technical Services
  • 541714Research and Development in Biotechnology (except Nanobiotechnology)
  • 541000Professional, Scientific, and Technical Services
  • 541700Scientific Research and Development Services
  • 541710Research and Development in the Physical, Engineering, and Life Sciences
SIC
  • 2800Chemicals And Allied Products
  • 2830Drugs
  • 2834Pharmaceutical Preparations
ISIC
  • 2100Manufacture of pharmaceuticals, medicinal chemical and botanical products
Show 14 more industry codes
NAICS
  • 320000Manufacturing
  • 325400Pharmaceutical and Medicine Manufacturing
  • 620000Health Care and Social Assistance
  • 325000Chemical Manufacturing
  • 623000Nursing and Residential Care Facilities
  • 325410Pharmaceutical and Medicine Manufacturing
  • 325412Pharmaceutical Preparation Manufacturing
SIC
  • 4000Railroad Transportation
  • 8000Health Services
  • 8700Engineering, Accounting, Research, Management, And Related Services
  • 8040Offices And Clinics Of Other Health Practitioners
  • 8730Research, Development, And Testing Services
  • 8049Offices And Clinics Of Health Practitioners, Not Elsewhere Classified
  • 8731Commercial Physical and Biological Research